Ali Alipour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ali Alipour has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Afra Darvishi
Student research committee, Tabriz University of Medical Sciences, Tabriz, 5166614756, Iran
4 shared publications - Amirreza Naseri
Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
3 shared publications - Hanieh Salehi-Pourmehr
Tabriz University of Medical Sciences
2 shared publications - Mahnaz Talebi
Neurosciences Research Center (NSRC) Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Amirhosein Dadashzadeh Asl
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication Malihe Talebi
Research Center for Evidence-Based Medicine, Iranian EBM Centre: A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication
Latest Publications
- Open Access
- 14 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The correlation between serum markers of oxidative stress and fatigue and related factors in minimally disabled patients with relapsing-remitting multiple sclerosis
Oxidative stress is recognized as a key pathological mechanism in multiple sclerosis (MS), and fatigue is one of the most prevalent and disabling symptoms. In this cross-sectional study, 85 patients diagnosed with relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) < 4.5 were recruited. Fatigue was evaluated by the Comprehensive Fatigue Assessment battery MS (CFAB-MS), which also assesses fatigue-related factors. Venous blood samples were collected to measure levels of glutathione peroxidase (GPX), catalase (CAT), malondialdehyde (MDA), reduced glutathione (GSH), total antioxidant capacity (TAC), and superoxide dismutase (SOD). Most correlations between oxidative stress markers and fatigue measures were not statistically significant. However, MDA levels showed significant positive correlations with Visual Analog Scale (VAS) scores for sleep problems (r:0.23, p-value:0.04); Walking problems VAS (r:0.31, p-value < 0.01); anxiety and worry (r:0.22, p-value < 0.05); and significant negative correlations with mood (r:-0.21, p-value < 0.05) and fatigue management (r:-0.22, p-value:0.04). Additionally, GSH levels were positively correlated with Fatigue VAS (r:0.24, p-value:0.02) and CAT was negatively correlated with stress VAS (r:-0.21, p-value:0.04). After applying the Benjamini-Hochberg correction, none of the correlations remained statistically significant. At an exploratory level, this study suggests that there is a minimal association between oxidative stress, fatigue and its related factors in minimally disabled RRMS patients.
- 14 May 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe correlation between serum markers of oxidative stress and fatigue and related factors in minimally disabled patients with relapsing-remitting multiple sclerosis
Oxidative stress is recognized as a key pathological mechanism in multiple sclerosis (MS), and fatigue is one of the most prevalent and disabling symptoms. In this cross-sectional study, 85 patients diagnosed with relapsing-remitting MS (RRMS) and Expanded Disability Status Scale (EDSS) < 4.5 were recruited. Fatigue was evaluated by the Comprehensive Fatigue Assessment battery MS (CFAB-MS), which also assesses fatigue-related factors. Venous blood samples were collected to measure levels of glutathione peroxidase (GPX), catalase (CAT), malondialdehyde (MDA), reduced glutathione (GSH), total antioxidant capacity (TAC), and superoxide dismutase (SOD). Most correlations between oxidative stress markers and fatigue measures were not statistically significant. However, MDA levels showed significant positive correlations with Visual Analog Scale (VAS) scores for sleep problems (r:0.23, p-value:0.04); Walking problems VAS (r:0.31, p-value < 0.01); anxiety and worry (r:0.22, p-value < 0.05); and significant negative correlations with mood (r:-0.21, p-value < 0.05) and fatigue management (r:-0.22, p-value:0.04). Additionally, GSH levels were positively correlated with Fatigue VAS (r:0.24, p-value:0.02) and CAT was negatively correlated with stress VAS (r:-0.21, p-value:0.04). After applying the Benjamini-Hochberg correction, none of the correlations remained statistically significant. At an exploratory level, this study suggests that there is a minimal association between oxidative stress, fatigue and its related factors in minimally disabled RRMS patients.
- 8 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106845
Antimuscarinics in multiple sclerosis: A systematic review
- 8 November 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 104, 106845
Antimuscarinics in multiple sclerosis: A systematic review
- Open Access
- 15 October 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-12
Serum markers and gastric cancer: an umbrella review
Early detection of gastric cancer (GC) is crucial for lowering the mortality risk and health burden. Since various biomarkers have been studied for the early diagnosis of GC, this umbrella focuses on the serum markers valuable in GC, for whether detecting or predicting the risk. Following the PRISMA statement and Joanna Briggs Institute (JBI) Manual, PubMed, Scopus, and Web of Science were searched before August 31, 2023. English-language systematic reviews that assessed the association between serum markers and the presence of and/or predicting the risk of GC with or without meta-analyses were included in this umbrella review. The chosen reviews assessed serum markers in GC, and the quality assessment was conducted by the JBI critical appraisal tool for systematic reviews. From 1441 records that remained after removing the duplicates, only seven were selected. The investigated serum markers in the studies included SOD activity, selenium, adiponectin dickkopf-1, pepsinogens, and autoantibodies. The bias risk in most of the included reviews was appropriately low. Overall, the SOD activity, circulating adiponectin, and selenium are suggested to be lower in patients with GC. Serum dickkopf-1 and serum pepsinogen are also proposed as potential biomarkers for GC. Considering the great heterogeneity between the studies, the possibility of publication bias, and the limited number of the included studies further investigation is required. The explained serum biomarkers could be helpful for diagnosis and predicting GC; however, further well-designed large-scale investigation is needed to ensure their clinical applications.
- 15 October 2025
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-12
Open AccessSerum markers and gastric cancer: an umbrella review
Early detection of gastric cancer (GC) is crucial for lowering the mortality risk and health burden. Since various biomarkers have been studied for the early diagnosis of GC, this umbrella focuses on the serum markers valuable in GC, for whether detecting or predicting the risk. Following the PRISMA statement and Joanna Briggs Institute (JBI) Manual, PubMed, Scopus, and Web of Science were searched before August 31, 2023. English-language systematic reviews that assessed the association between serum markers and the presence of and/or predicting the risk of GC with or without meta-analyses were included in this umbrella review. The chosen reviews assessed serum markers in GC, and the quality assessment was conducted by the JBI critical appraisal tool for systematic reviews. From 1441 records that remained after removing the duplicates, only seven were selected. The investigated serum markers in the studies included SOD activity, selenium, adiponectin dickkopf-1, pepsinogens, and autoantibodies. The bias risk in most of the included reviews was appropriately low. Overall, the SOD activity, circulating adiponectin, and selenium are suggested to be lower in patients with GC. Serum dickkopf-1 and serum pepsinogen are also proposed as potential biomarkers for GC. Considering the great heterogeneity between the studies, the possibility of publication bias, and the limited number of the included studies further investigation is required. The explained serum biomarkers could be helpful for diagnosis and predicting GC; however, further well-designed large-scale investigation is needed to ensure their clinical applications.
- Open Access
- 29 September 2025
- Published by Maad Rayan Publishing Company in Biomedical Research Bulletin
- Vol. 3 (3) , 149-152
Shark-Derived Neuroprotective Agents for Neurodegenerative Diseases: From Molecular Pathways to Clinical Evidence
Neurodegenerative diseases, such as (but not limited to) Alzheimer’s disease and Parkinson’s disease, are a serious global health problem. Considering that the current treatments are primarily focused on symptom relief, it is necessary to find novel therapeutic approaches, including target therapies. Sharks have a special biochemical potential, and various neuroprotective agents can be derived from these animals. This review aims to evaluate and summarize the data available on shark-derived compounds in the case of neurodegeneration, explaining the molecular signatures and insights for novel therapies. Squalamine, trodusquemine, and single domain antibodies are the major products discussed in this paper. This review study further provides molecular pathways and clinical and animal data due to date, suggesting promising insights into more investigations in this field.
- 29 September 2025
- Published by Maad Rayan Publishing Company in Biomedical Research Bulletin
- Vol. 3 (3) , 149-152
Open AccessShark-Derived Neuroprotective Agents for Neurodegenerative Diseases: From Molecular Pathways to Clinical Evidence
Neurodegenerative diseases, such as (but not limited to) Alzheimer’s disease and Parkinson’s disease, are a serious global health problem. Considering that the current treatments are primarily focused on symptom relief, it is necessary to find novel therapeutic approaches, including target therapies. Sharks have a special biochemical potential, and various neuroprotective agents can be derived from these animals. This review aims to evaluate and summarize the data available on shark-derived compounds in the case of neurodegeneration, explaining the molecular signatures and insights for novel therapies. Squalamine, trodusquemine, and single domain antibodies are the major products discussed in this paper. This review study further provides molecular pathways and clinical and animal data due to date, suggesting promising insights into more investigations in this field.